Note: This document has been translated from the Japanese original for reference purpose only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 10, 2026

Noevir Holdings Announces 2026 Consolidated Results (based on Japan GAAP)

Trade name: Noevir Holdings Co., Ltd.
Listing: Tokyo Stock Exchange, Prime Market (Securities Code: 4928)
URL: https://www.noevirholdings.co.jp/
Representative: Takashi Okura, President and CEO
Contact: Junya Baba, General Manager, Accounting
Tel. +81-78-303-5121

Annual General Meeting of Shareholders: December 9, 2026
Date of commencement of dividend payments: December 10, 2026
Submission of securities report: December 8, 2026
Supplemental materials for the financial results prepared: Yes
Results briefing for the reporting period held: Yes (for institutional investors and analysts)

(Amounts under one million yen have been rounded down)

1. Operating results for the fiscal year ended September 30, 2026 (October 1, 2025 to September 30, 2026)

(1) Consolidated operating results

(Millions of yen; percentage figures denote year-on-year change)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent
Fiscal year ended September 30, 2026	62,651 (3.2) %	9,424 (14.9) %	9,896 (16.0) %	8,216 2.3 %
Fiscal year ended September 30, 2025	64,724 1.4 %	11,075 (3.0) %	11,774 1.6 %	8,030 0.8 %

Note: Comprehensive income:
Fiscal year ended September 30, 2026: 8,513 million yen [4.6%]
Fiscal year ended September 30, 2025: 8,142 million yen [(2.1)%]

	EPS (Yen)	Diluted EPS (Yen)	ROE (%)	Ordinary income/ Total assets (%)	Operating income/ Total sales (%)
Fiscal year ended September 30, 2026	240.56	—	15.2	13.0	15.0
Fiscal year ended September 30, 2025	235.10	—	15.0	15.4	17.1

[Reference]
Equity in gain/losses of affiliated companies
Fiscal year ended September 30, 2026: — million yen
Fiscal year ended September 30, 2025: — million yen

(2) Consolidated financial position

(Millions of yen)

	Total assets	Net assets	Equity ratio (%)	Net assets per share (Yen)
As of September 30, 2026	75,448	54,630	71.8	1,585.54
As of September 30, 2025	76,492	54,209	70.3	1,574.17

[Reference] Equity:
As of September 30, 2026: 54,155 million yen
As of September 30, 2025: 53,767 million yen

(3) Consolidated cash flows

(Millions of yen)

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents, end of year
Fiscal year ended September 30, 2026	4,676	2,072	(8,178)	25,458
Fiscal year ended September 30, 2025	7,928	(2,417)	(7,924)	26,723

2. Cash dividends

	Annual dividends (Yen)					Total dividend amount (Millions of yen) (Annual)	Payout ratio (%) (Consolidated)	Dividends/ Shareholders' equity (%) (Consolidated)
	1st quarter	2nd quarter	3rd quarter	Year-end	Total			
Fiscal year ended September 30, 2025	—	0.00	—	230.00	230.00	7,855	97.8	14.7
Fiscal year ended September 30, 2026	—	0.00	—	232.00	232.00	7,924	96.4	14.7
Fiscal year ending September 30, 2027 (forecast)	—	0.00	—	232.00	232.00		95.5	

3. Consolidated earnings forecasts for the fiscal year ending September 30, 2027 (October 1, 2026 to September 30, 2027)

(Millions of yen; percentage figures denote year-on-year change)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of the parent		EPS (Yen)
Full year	64,300	2.6%	10,400	10.4%	10,800	9.1%	8,300	1.0%	243.00

* Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies, changes in accounting estimates, and restatement
1) Changes associated with revision in accounting standards: None
2) Other changes: None
3) Changes in accounting estimates: None
4) Restatement: None

(3) Shares outstanding (common stock)
1) Shares outstanding (including treasury stock)
As of September 30, 2026: 34,156,623
As of September 30, 2025: 34,156,623
2) Treasury shares outstanding
As of September 30, 2026: 417
As of September 30, 2025: 416
3) Average shares outstanding over quarter
Fiscal year ended September 30, 2026: 34,156,207
Fiscal year ended September 30, 2025: 34,156,207

Note: Please refer to "Note on per-share information" on page 19 of the Attached Material regarding the formula used to calculate earnings per share (consolidated).

* Financial results reports are exempt from audit conducted by certified public accountants or an audit firm.

* Explanation regarding the appropriate use of business performance forecasts

Forward-looking statements included in these materials, such as forecasts of business performance, are based on information known to the Company's management as of the time of writing, and reflect judgments believed to be reasonable on the basis of that information. There is, therefore, a possibility that actual business performance figures will differ substantially from our forecasts as a result of changes in the economic situation and other unforeseeable factors. Please refer to "(1) Operating results for the fiscal year ended September 30, 2026" under "1. Operating results and financial information" on page 4 of Attached Material.

Contents of the Attached Material

1. Operating results and financial information 4
(1) Operating results for the fiscal year ended September 30, 2026..... 4
(2) Financial position as of September 30, 2026..... 6
(3) Profit distribution/dividend payment for the reporting term and the current term..... 6

2. Management strategy..... 7
(1) Basic management policies and medium- to long-term strategy 7
(2) Numerical targets and achievements 7
(3) Key issues..... 7

3. Basic Approach to Selecting Accounting Principles 7

4. Consolidated financial statements and notes 8
(1) Consolidated balance sheets 8
(2) Consolidated statements of income and comprehensive income..... 10
(3) Consolidated changes to equity 12
(4) Consolidated statements of cash flows..... 14
(5) Notes to consolidated financial statements..... 15
(Note on assumptions for going concern)..... 15
(Note on consolidated balance sheets)..... 15
(Note on segment information, etc.)..... 15
(Note on per-share information)..... 19
(Note on important subsequent events) 19

1. Operating results and financial information

(1) Operating results for the fiscal year ended September 30, 2026

1) Consolidated operating results for the reporting fiscal period

<<Background>>

	Fiscal year ended September 30, 2025		Fiscal year ended September 30, 2026		Change (Millions of yen)	Change (%)
	Net sales (Millions of yen)	% of Total	Net sales (Millions of yen)	% of Total		
Net sales	64,724	100.0	62,651	100.0	(2,073)	(3.2)
Cosmetics	50,525	78.1	49,055	78.3	(1,469)	(2.9)
Pharmaceuticals & Health Food	11,535	17.8	11,049	17.6	(486)	(4.2)
Other	2,664	4.1	2,546	4.1	(117)	(4.4)

	Fiscal year ended September 30, 2025		Fiscal year ended September 30, 2026		Change (Millions of yen)	Change (%)
	Amount (Millions of yen)	% of Net sales	Amount (Millions of yen)	% of Net sales		
Operating income	11,075	17.1	9,424	15.0	(1,651)	(14.9)
Ordinary income	11,774	18.2	9,896	15.8	(1,878)	(16.0)
Net income attributable to owners of the parent	8,030	12.4	8,216	13.1	186	2.3

During fiscal 2026 (October 1, 2025 to September 30, 2026), economic trends remained uncertain due to factors such as the impact of conditions in the Middle East, although some signs of a moderate recovery were observed.

In this environment, the Company is working to realize the concept of its medium- to long-term strategy: “Realizing steady corporate growth by securing sustainability in every Group business segment.”

As a result, net sales for the fiscal year ended September 30, 2026 came to 62,651 million yen (down 3.2% year on year), operating income was 9,424 million yen (down 14.9%), ordinary income was 9,896 million yen (down 16.0%), and net income attributable to owners of the parent came to 8,216 million yen (up 2.3%). Notably, net income attributable to owners of the parent was a record high.

<<Segment results>>

(a) Cosmetics

(Millions of yen)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2026	Change (Millions of yen)	Change (%)
Net sales	50,525	49,055	(1,469)	(2.9)
Segment income	12,292	11,066	(1,226)	(10.0)

Sales in the Cosmetics segment totaled 49,055 million yen (down 2.9% year on year), and segment income came to 11,066 million yen (down 10.0%).

(b) Pharmaceuticals & Health Food

(Millions of yen)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2026	Change (Millions of yen)	Change (%)
Net sales	11,535	11,049	(486)	(4.2)
Segment income	980	666	(313)	(32.0)

Sales in the Pharmaceuticals & Health Food segment totaled 11,049 million yen (down 4.2% year on year), and segment income came to 666 million yen (down 32.0%).

(c) Other

(Millions of yen)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2026	Change (Millions of yen)	Change (%)
Net sales	2,664	2,546	(117)	(4.4)
Segment income	301	286	(14)	(4.9)

Sales in the Other segment came to 2,546 million yen (down 4.4% year on year), and segment income came to 286 million yen (down 4.9%).

2) Forecast for the current fiscal year ending September 30, 2027

Although a gradual economic recovery is anticipated, the outlook is expected to remain uncertain due to factors such as the risk of downward pressure on consumer spending caused by rising prices.
In this environment, the Company will move forward aiming to realize the concept of its medium- to long-term strategy: “Realizing steady corporate growth by securing sustainability in every Group business segment.” With this aim in mind, the Company’s consolidated forecast for the fiscal year ending September 30, 2027 is for net sales of 64,300 million yen, operating income of 10,400 million yen, ordinary income of 10,800 million yen, and net income attributable to owners of the parent of 8,300 million yen.

(2) Financial position as of September 30, 2026

1) Assets, liabilities and net assets

Total assets on a consolidated basis as of September 30, 2026 stood at 75,448 million yen, a decrease of 1,044 million yen from the previous fiscal year-end. This was mainly due to decreases in cash and deposits of 1,263 million yen, notes and accounts receivable of 800 million yen, and land of 488 million yen, while there was an increase in merchandise and finished goods of 1,892 million yen.
Total liabilities came to 20,817 million yen, a decrease of 1,465 million yen from the previous fiscal year-end. This mainly reflected decreases in income tax payable of 483 million yen, guarantee deposits received of 395 million yen, and notes and accounts payable of 352 million yen.
Net assets came to 54,630 million yen, an increase of 420 million yen from the previous fiscal year-end. This was primarily attributable to an increase in retained earnings of 360 million yen, due to the payment of 7,855 million yen in dividends at the previous fiscal year-end, which was partly offset by net income attributable to owners of the parent of 8,216 million yen.

As a result, the equity ratio stood at 71.8%, up 1.5 percentage points from the previous fiscal year-end, and net assets per share stood at 1,585.54 yen, an increase of 11.37 yen.

2) Consolidated cash flows

Cash and cash equivalents (hereinafter, “cash”) on a consolidated basis as of September 30, 2026 stood at 25,458 million yen, a decrease of 1,264 million yen compared with the previous fiscal year-end.
The status of each cash flow together with the factors contributing to their increase or decrease for the fiscal year ended September 30, 2026 are presented as follows.

(Cash flows from operating activities)
Net cash provided by operating activities amounted to 4,676 million yen (compared with an inflow of 7,928 million yen in the previous fiscal year). The main item increasing cash was 11,992 million yen in income before income taxes, while the main items decreasing cash were 3,937 million yen in net income tax paid and 1,944 million yen in increase in inventories.

(Cash flows from investing activities)
Net cash provided by investing activities came to 2,072 million yen (compared with an outflow of 2,417 million yen in the previous fiscal year). The principal cash inflows were 1,502 million yen in proceeds from sale of investment securities and 1,433 million yen in proceeds from sale of property, plant and equipment, whereas the principal cash outflow was 742 million yen for purchase of property, plant and equipment.

(Cash flows from financing activities)
Net cash used in financing activities came to 8,178 million yen (compared with an outflow of 7,924 million yen in the previous fiscal year). This was mainly due to the payment of 7,855 million yen in dividends.

(3) Profit distribution/dividend payment for the reporting term and the current term

The Company regards profit distribution to shareholders as an important management issue. Therefore, its basic policy is to continue to pay dividends with a focus on returning profits to shareholders while ensuring the necessary reserves for business expansion in the medium and long term and a stronger management structure. For fiscal 2026 (ended September 30, 2026), based on the aforementioned policy, we plan to pay a year-end dividend of 232 yen per share, which is a 2 yen increase from our most recent dividend forecast.
For the current fiscal year, ending September 30, 2027, we plan to pay a dividend of 232 yen per share.

2. Management strategy

(1) Basic management policies and medium- to long-term strategy

To achieve the concept underlying the Noevir Group's medium- to long-term strategy, "Realizing steady corporate growth by securing sustainability in every Group business segment," the Group will execute the following five policies:

1. Pursue innovation and continuous profit generation in the domestic market
2. Enhance our brand value
3. Accelerate efforts to diversify human resources and our corporate structure
4. Strengthen our competitiveness by stepping up the diversification of our R&D, production and logistics systems
5. Promote a management approach that is responsive to changes in the business environment

(2) Numerical targets and achievements

Having positioned net sales, operating income and return on equity (ROE) as key management indicators, the Noevir Group aims to maximize its corporate value and enhance profitability.

(3) Key issues

Although a gradual economic recovery is anticipated, the outlook is expected to remain uncertain due to factors such as the risk of downward pressure on consumer spending caused by rising prices.
In this environment, in order to respond to change and diversification in the markets for the Group's core Cosmetics and Pharmaceuticals & Health Food businesses, the Group recognizes that promoting its concept underlying the medium- to long-term strategy, "Realizing steady corporate growth by securing sustainability in every Group business segment" is an important priority.

3. Basic Approach to Selecting Accounting Principles

For the foreseeable future, the Group plans to prepare consolidated financial statements based on generally accepted accounting principles in Japan. This policy takes into account factors such as the need to maintain comparability between the accounting periods of the consolidated financial statements and the fact that the Group has very little need to procure funds in overseas markets. Going forward, the Group plans to give due consideration to the adoption of international financial reporting standards (IFRS), taking into account conditions in Japan and overseas.

4. Consolidated financial statements and notes

(1) Consolidated balance sheets

(Millions of yen)

	As of September 30, 2025	**As of September 30, 2026**
ASSETS		
Current assets		
Cash and deposits	26,930	**25,667**
Notes and accounts receivable	12,110	**11,310**
Merchandise and finished goods	5,974	**7,866**
Work in progress	183	**174**
Raw materials and purchased supplies	1,525	**1,665**
Other	2,166	**2,630**
Allowance for doubtful accounts	(7)	**(7)**
Total current assets	48,884	**49,307**
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	4,419	**4,057**
Equipment and vehicles, net	547	**469**
Land	14,976	**14,488**
Lease assets, net	686	**613**
Construction in progress	545	**822**
Other, net	221	**257**
Total property, plant and equipment	*1 21,397	*1 **20,709**
Intangible assets		
Goodwill	125	**91**
Software	89	**789**
Other	969	**122**
Total intangible assets	1,184	**1,002**
Investments and other assets		
Investment securities	2,866	**2,578**
Deferred tax assets	1,070	**1,124**
Other	1,106	**740**
Allowance for doubtful accounts	(17)	**(15)**
Total investments and other assets	5,026	**4,428**
Total non-current assets	27,608	**26,140**
Total assets	76,492	**75,448**

(Millions of yen)

	As of September 30, 2025	**As of September 30, 2026**
LIABILITIES		
Current liabilities		
Notes and accounts payable	3,240	**2,887**
Lease obligations	85	**85**
Other accounts payable	2,160	**2,133**
Income tax payable	2,043	**1,560**
Provision for bonuses	25	**4**
Other	2,290	**2,243**
Total current liabilities	9,847	**8,914**
Long-term liabilities		
Lease obligations	657	**579**
Guarantee deposits received	10,751	**10,356**
Deferred tax liabilities	690	**731**
Other	336	**236**
Total long-term liabilities	12,436	**11,903**
Total liabilities	22,283	**20,817**
NET ASSETS		
Shareholders' equity		
Common stock	7,319	**7,319**
Retained earnings	44,113	**44,473**
Treasury stock	(2)	**(2)**
Total shareholders' equity	51,429	**51,790**
Accumulated other comprehensive income		
Net unrealized gain on other securities	1,751	**1,584**
Foreign currency translation adjustments	585	**781**
Total accumulated other comprehensive income	2,337	**2,365**
Non-controlling interests	441	**474**
Total net assets	54,209	**54,630**
Total liabilities and net assets	76,492	**75,448**

(2) Consolidated statements of income and comprehensive income

Consolidated statements of income

(Millions of yen)

	Fiscal year ended September 30, 2025	**Fiscal year ended September 30, 2026**
Net sales	64,724	**62,651**
Cost of sales	21,446	**20,372**
Gross profit	43,278	**42,278**
Selling, general and administrative expenses		
Sales commission	8,143	**8,018**
Cost of sales	2,767	**2,714**
Salaries and bonuses	6,483	**6,632**
Accrued allowance for bonuses	21	**22**
Retirement benefits for employees	348	**331**
Other	14,438	**15,133**
Total	32,202	**32,854**
Operating income	11,075	**9,424**
Non-operating income		
Interest income	94	**151**
Dividend income	32	**44**
Gain on currency translation	48	**17**
Rental income	34	**24**
Insurance claim income	200	**0**
Dividend income of insurance	94	**61**
Compensation for damages received	105	**63**
Other	91	**109**
Total	702	**472**
Non-operating expenses		
Other	3	**0**
Total	3	**0**
Ordinary income	11,774	**9,896**
Extraordinary income		
Gain on sale of non-current assets	22	**932**
Gain on sale of investment securities	―	**1451**
Gain on revision of retirement benefit plan	85	**―**
Total	108	**2384**
Extraordinary losses		
Loss on disposal of non-current assets	3	**3**
Impairment loss	―	**120**
Loss on cancellation of insurance policies	―	**164**
Total	3	**288**
Income before income taxes	11,879	**11,992**
Income taxes – basic	3,497	**3,510**
Income taxes – deferred	192	**57**
Total	3,690	**3,567**
Net income	8,189	**8,424**
Net income attributable to non-controlling interests	159	**208**
Net income attributable to owners of the parent	8,030	**8,216**

Consolidated statements of comprehensive income

(Millions of yen)

	Fiscal year ended September 30, 2025	**Fiscal year ended September 30, 2026**
Net income	8,189	**8,424**
Other comprehensive income		
Net unrealized gain on other securities	(199)	**(167)**
Foreign currency translation adjustments	132	**256**
Remeasurements of defined benefit plans, net of tax	20	**—**
Total	(46)	**88**
Comprehensive income	8,142	**8,513**
(Breakdown)		
Comprehensive income attributable to owners of the parent	7,974	**8,244**
Comprehensive income attributable to non-controlling interests	168	**269**

(3) Consolidated changes to equity

Fiscal year ended (September 30, 2025)

(Millions of yen)

	Shareholders' equity			
	Common stock	Retained earnings	Treasury stock	Total shareholders' equity
Balance at beginning of the year	7,319	43,768	(2)	51,084
Changes during the reporting period				
Distribution of dividends from retained earnings		(7,685)		(7,685)
Net income attributable to owners of the parent		8,030		8,030
Changes during the reporting period, excluding shareholders' equity				
Total changes during the period	—	345	—	345
Balance at end of the year	7,319	44,113	(2)	51,429

	Accumulated other comprehensive income				Non-controlling interests	Total net assets
	Net unrealized gain on other securities	Foreign currency translation adjustments	Remeasure-ments of defined benefit plans	Total accumulated other comprehensive income		
Balance at beginning of the year	1,951	461	(20)	2,392	428	53,906
Changes during the reporting period						
Distribution of dividends from retained earnings						(7,685)
Net income attributable to owners of the parent						8,030
Changes during the reporting period, excluding shareholders' equity	(199)	124	20	(55)	12	(42)
Total changes during the period	(199)	124	20	(55)	12	302
Balance at end of the year	1,751	585	—	2,337	441	54,209

Fiscal year ended (September 30, 2026)

(Millions of yen)

	Shareholders' equity			
	Common stock	Retained earnings	Treasury stock	Total shareholders' equity
Balance at beginning of the year	7,319	44,113	(2)	51,429
Changes during the reporting period				
Distribution of dividends from retained earnings		(7,855)		(7,855)
Net income attributable to owners of the parent		8,216		8,216
Purchase of treasury stock			(0)	(0)
Changes during the reporting period, excluding shareholders' equity				
Total changes during the period	—	360	(0)	360
Balance at end of the year	7,319	44,473	(2)	51,790

	Accumulated other comprehensive income			Non-controlling interests	Total net assets
	Net unrealized gain on other securities	Foreign currency translation adjustments	Total accumulated other comprehensive income		
Balance at beginning of the year	1,751	585	2,337	441	54,209
Changes during the reporting period					
Distribution of dividends from retained earnings					(7,855)
Net income attributable to owners of the parent					8,216
Purchase of treasury stock					(0)
Changes during the reporting period, excluding shareholders' equity	(167)	195	27	32	60
Total changes during the period	(167)	195	27	32	420
Balance at end of the year	1,584	781	2,365	474	54,630

(4) Consolidated statements of cash flows

(Millions of yen)

	Fiscal year ended September 30, 2025	**Fiscal year ended September 30, 2026**
Cash flows from operating activities		
Income before income taxes	11,879	**11,992**
Depreciation	832	**1,025**
Impairment loss	―	**120**
Amortization of goodwill	33	**33**
Increase (decrease) in allowance for doubtful accounts	(0)	**(2)**
Increase (decrease) in provision for bonuses	(71)	**(21)**
Increase (decrease) in net defined benefit asset and liability	(462)	**1**
Increase (decrease) in accounts payable due to transition to a retirement benefit plan	304	**(115)**
Interest and dividends received	(126)	**(196)**
Loss (gain) on currency translation	(32)	**(21)**
Loss (gain) on sale of investment securities	―	**(1,451)**
Loss (gain) on sales of disposal of non-current assets	(19)	**(929)**
Gain on revision of retirement benefit plan	(85)	**―**
Decrease (increase) in trade receivables	(1,298)	**840**
Decrease (increase) in inventories	439	**(1,944)**
Increase (decrease) in trade payables	276	**(375)**
Increase (decrease) in guarantee deposits	(413)	**(395)**
Other	(168)	**(362)**
Subtotal	11,088	**8,197**
Interest and dividends received	69	**186**
Income tax (paid) refunded	(3,229)	**(3,937)**
Surrender value of insurance policies received	―	**229**
Net cash provided by (used in) operating activities	7,928	**4,676**
Cash flows from investing activities		
Expenditure for deposit to time deposits	(207)	**(208)**
Proceeds from withdrawal of time deposits	217	**207**
Purchase of securities	(19,985)	**(14,925)**
Proceeds from redemption of securities	20,038	**14,925**
Purchase of investment securities	(1)	**(1)**
Proceeds from sale of investment securities	―	**1,502**
Purchase of property, plant and equipment	(2,266)	**(742)**
Proceeds from sale of property, plant and equipment	40	**1,433**
Purchase of intangible assets	(252)	**(117)**
Net cash provided by (used in) investing activities	(2,417)	**2,072**
Cash flows from financing activities		
Purchase of treasury stock	―	**(0)**
Cash dividends paid	(7,683)	**(7,855)**
Cash dividends paid to non-controlling interests	(155)	**(237)**
Other	(85)	**(85)**
Net cash provided by (used in) financing activities	(7,924)	**(8,178)**
Effects of exchange rate changes on cash and cash equivalents	130	**164**
Net change in cash and cash equivalents	(2,283)	**(1,264)**
Cash and cash equivalents, beginning of the period	29,006	**26,723**
Cash and cash equivalents, end of the period	26,723	**25,458**

(5) Notes to consolidated financial statements

(Note on assumptions for going concern)

Not applicable

(Note on consolidated balance sheets)

*1. Accumulated depreciation of property, plant and equipment is as follows.

(Millions of yen)

	As of September 30, 2025	As of September 30, 2026
Accumulated depreciation of property, plant and equipment	32,097	32,095

(Note on segment information, etc.)

(Segment information)

1) Reportable segments

The Company's reportable segments are the subject of regular management review, for the purposes of decision-making for resource allocation and performance evaluation by the Board of Directors, in as much as financial information relating to individual units of the Company are available.

The Group engages principally in the manufacture and marketing of cosmetics, pharmaceuticals and health foods, as well as operating other businesses including apparel- and aviation-related businesses.

The Group's business activities are based on strategies tailored to the changing and diversifying market environment.

Accordingly, the Group has the following three reportable segments, comprising business segments based on the products handled by the Group.

The Cosmetics segment manufactures and markets cosmetics products.

In the Pharmaceuticals & Health Food segment, the Company manufactures and sells pharmaceuticals and food products.

In the Other segment, we mainly operate apparel-businesses, purchase and sale of aircraft and vessels, aviation-related operations, pilot training operations and others.

2) Method for calculating sales, income and loss, assets, liabilities and other item amounts in each reporting segment

The accounting procedure for reporting business segments is largely the same as described in Basis for Presentation of Consolidated Financial Reports, which was disclosed in the latest securities report (submitted December 8, 2025).

Reportable segment income figures are on an operating income basis. Internal rates of return and transfer within the Group are based on the actual market price.

3) Information concerning sales, income and loss, assets, liabilities and other item amounts in each reporting segment and revenue breakdown information

Consolidated results for fiscal 2025 (October 1, 2024 to September 30, 2025)

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Total	Adjustment (Note 1)	Amounts included in consolidated statements of income (Note 2)
Net sales						
Revenue from contracts with customers	50,525	11,535	2,570	64,631	—	64,631
Other revenue	—	—	93	93	—	93
Sales, external	50,525	11,535	2,664	64,724	—	64,724
Intersegment sales	—	—	266	266	(266)	—
Total	50,525	11,535	2,930	64,991	(266)	64,724
Segment income	12,292	980	301	13,573	(2,498)	11,075
Segment assets	50,423	14,333	2,489	67,246	9,246	76,492
Other items						
Depreciation	511	281	39	832	—	832
Amortization of goodwill	0	2	31	33	—	33
Increases of property, plant and equipment and intangible assets	2,209	340	5	2,555	—	2,555

(Note 1) Adjustments are as follows.

1) Intersegment eliminations totaling 452 million yen and unallocated corporate expenses totaling (2,950) million yen have been included in the segment income adjustment totaling (2,498) million yen. Corporate expenses refer to parent company administration costs which do not come under any reportable segments.
2) The segment income adjustment is for assets of the entire Company that are not allocated to each reportable segment. Assets of the entire Company are primarily the Company's financial assets (cash and cash equivalents, investment securities, etc.) that do not belong to reporting segments and assets related to administrative divisions.
3) The depreciation adjustment is for the depreciation of assets related to elimination/corporate.

(Note 2) Segment income or loss refers to operating income as reported in the consolidated statements of income, after adjustment.

Consolidated results for fiscal 2026 (October 1, 2025 to September 30, 2026)

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Total	Adjustment (Note 1)	Amounts included in consolidated statements of income (Note 2)
Net sales						
Revenue from contracts with customers	49,055	11,049	2,451	62,556	—	62,556
Other revenue	—	—	94	94	—	94
Sales, external	49,055	11,049	2,546	62,651	—	62,651
Intersegment sales	—	—	303	303	(303)	—
Total	49,055	11,049	2,849	62,954	(303)	62,651
Segment income	11,066	666	286	12,018	(2,594)	9,424
Segment assets	50,999	13,391	2,003	66,394	9,053	75,448
Other items						
Depreciation	707	288	29	1,025	—	1,025
Amortization of goodwill	0	2	31	33	—	33
Increases of property, plant and equipment and intangible assets	444	90	266	802	—	802

(Note 1) Adjustments are as follows.

1) Intersegment eliminations totaling 454 million yen and unallocated corporate expenses totaling (3,049) million yen have been included in the segment income adjustment totaling (2,594) million yen. Corporate expenses refer to parent company administration costs which do not come under any reportable segments.
2) The segment income adjustment is for assets of the entire Company that are not allocated to each reportable segment. Assets of the entire Company are primarily the Company's financial assets (cash and cash equivalents, investment securities, etc.) that do not belong to reporting segments and assets related to administrative divisions.
3) The depreciation adjustment is for the depreciation of assets related to elimination/corporate.

(Note 2) Segment income refers to operating income as reported in the consolidated statements of income, after adjustment.

(Impairment loss for non-current assets by reportable segment)

Previous fiscal year (October 1, 2024 to September 30, 2025)

Not applicable

Reporting fiscal year (October 1, 2025 to September 30, 2026)

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Elimination/ corporate (total)	Total
Impairment loss	―	120	―	―	120

(Amortization and unamortized balance of goodwill for each reportable segment)

Previous fiscal year (October 1, 2024 to September 30, 2025)

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Elimination/ corporate (total)	Total
Balance at the end of the year	0	8	116	―	125

(Note) Amortization of goodwill is omitted because similar information is disclosed in Segment Information.

Reporting fiscal year (October 1, 2025 to September 30, 2026)

(Millions of yen)

	Cosmetics	Pharmaceuticals & Health Food	Other	Elimination/ corporate (total)	Total
Balance at the end of the year	0	6	85	―	91

(Note) Amortization of goodwill is omitted because similar information is disclosed in Segment Information.

(Information about gain on bargain purchase for each reportable segment)

Previous fiscal year (October 1, 2024 to September 30, 2025)

Not applicable

Reporting fiscal year (October 1, 2025 to September 30, 2026)

The information is omitted due to immateriality.

(Note on per-share information)

(Yen)

	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2026
Net assets per share	1,574.17	1,585.54
Net income per share	235.10	240.56

Notes: 1. Diluted income per share is not disclosed since there were no potentially dilutive shares.

2. The basis for calculation of net assets per share is as follows.

Item	As of September 30, 2025	As of September 30, 2026
Total net assets (millions of yen)	54,209	54,630
Amount deducted from total net assets (millions of yen)	441	474
(Of which, non-controlling interests) (millions of yen)	(441)	(474)
Net assets at the end of the period attributable to common stock (millions of yen)	53,767	54,155
Number of common shares at the fiscal year-end used for calculation of net assets per share (shares)	34,156,207	34,156,206

3. The basis for calculation of net income per share is as follows.

Item	Fiscal year ended September 30, 2025	Fiscal year ended September 30, 2026
Net income attributable to owners of the parent (millions of yen)	8,030	8,216
Amount not attributable to ordinary shareholders (millions of yen)	—	—
Net income attributable to owners of the parent (millions of yen)	8,030	8,216
Average number of common shares for the period (shares)	34,156,207	34,156,207

(Note on important subsequent events)

Not applicable